Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting
October 09, 2023 08:30 ET
|
Tenaya Therapeutics, Inc.
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6...
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
October 05, 2023 08:30 ET
|
Tenaya Therapeutics, Inc.
Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration
October 02, 2023 17:30 ET
|
Tenaya Therapeutics, Inc.
Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.
Global Cardiac Arrest Treatment Market: Forecasted Growth to Reach USD 8.3 Billion by 2030, At a CAGR of 4.5%
October 02, 2023 17:29 ET
|
Zion Market Research
NEW YORK, United States, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Cardiac Arrest Treatment Market By Treatment (Drugs [Vasopressors,...
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference
August 31, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 09, 2023 16:05 ET
|
Tenaya Therapeutics, Inc.
Dosing of First Patient in Phase 1b Trial of TN-201 On Track to Occur in Q3 2023 Data from Phase 1 Clinical Trial of TN-301 Accepted for Presentation at HFSA 2023 IND Application for TN-401...
HealthTab™ Signs Reseller Agreement With Abbott to Support UK Expansion
August 08, 2023 11:54 ET
|
Avricore Health Inc.
VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased to announce the signing of a reseller...
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
July 10, 2023 07:37 ET
|
ZyVersa Therapeutics
Mechanical stress on the heart, such as high blood pressure, initiates NLRP3-induced inflammation through heart-brain interactions, causing heart enlargement (hypertrophic heart disease) Mechanical...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
June 26, 2023 20:25 ET
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...